ImmunoPrecise Antibodies Ltd. (IPA) Reports Q1 Loss, Misses Revenue Estimates

Company Performance - ImmunoPrecise Antibodies Ltd. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, and the same as the loss reported a year ago [1] - The company posted revenues of $3.85 million for the quarter ended July 2024, missing the Zacks Consensus Estimate by 22.44%, compared to revenues of $4.26 million a year ago [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Performance - ImmunoPrecise Antibodies shares have declined approximately 60.8% since the beginning of the year, while the S&P 500 has gained 18% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $5.4 million, and for the current fiscal year, it is -$0.25 on revenues of $21.75 million [7] Industry Outlook - The Medical Info Systems industry, to which ImmunoPrecise Antibodies belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]